Robert Huston

Dr. Robert Huston


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
Veronique Demers-MathieuVeronique Demers-Mathieu
Veronique Demers-Mathieu
RHRobert Huston
Robert Huston
AMAndi M. Markell
Andi M. Markell
EMElizabeth A. McCulley
Elizabeth A. McCulley
RMRachel L. Martin
Rachel L. Martin
DDDavid Dallas
David Dallas
Maternal antibody transfer to the newborn provides essential support for the infant’s naïve immune system. Preterm infants normally receive maternal antibodies through mother’s own breast milk (MBM) or, when mothers are unable to provide all the milk required, donor breast milk (DBM). DBM is pasteurized and exposed to several freeze–thaw cycles, which could reduce intact antibody concentration and the antibody’s resistance to digestion within the infant. Whether concentrations of antibodies in MBM and DBM differ and whether their survival across digestion in preterm infants differs remains unknown. Feed (MBM or DBM), gastric contents (MBM or DBM at 1-h post-ingestion) and stool samples (collected after a mix of MBM and DBM feeding) were collected from 20 preterm (26–36 weeks gestational age) mother–infant pairs at 8–9 and 21–22 days of postnatal age. Samples were analyzed via ELISA for the concentration of secretory IgA (SIgA), total IgA (SIgA/IgA), total IgM (SIgM/IgM) and IgG. Total IgA, SIgA, total IgM and IgG concentrations were 55.0%, 71.6%, 98.4% and 41.1% higher in MBM than in DBM, and were 49.8%, 32.7%, 73.9% and 39.7% higher in gastric contents when infants were fed with MBM than when infants were fed DBM, respectively. All maternal antibody isotypes present in breast milk were detected in the infant stools, of which IgA (not sIgA) was the most abundant.

16 February 2018 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
PDF file
RHRobert Huston
Robert Huston
AMAndrea M. Markell
Andrea M. Markell
EMElizabeth A. McCulley
Elizabeth A. McCulley
SGStuart K. Gardiner
Stuart K. Gardiner
SSSean L. Sweeney
Sean L. Sweeney

11 July 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
Veronique Demers-MathieuVeronique Demers-Mathieu
Veronique Demers-Mathieu
RHRobert Huston
Robert Huston
AMAndi M. Markell
Andi M. Markell
EMElizabeth A. McCulley
Elizabeth A. McCulley
RMRachel L. Martin
Rachel L. Martin
DDDavid Dallas
David Dallas
Antenatal milk anti-influenza antibodies may provide additional protection to newborns until they are able to produce their own antibodies. To evaluate the relative abundance of milk, we studied the antibodies specific to influenza A in feeds and gastric contents and stools from preterm infants fed mother’s own breast milk (MBM) and donor breast milk (DBM). Feed (MBM or DBM) and gastric contents (MBM or DBM at 1 h post-ingestion) and stool samples (MBM/DBM at 24 h post-ingestion) were collected, respectively, from 20 preterm (26–36 weeks gestational age) mother-infant pairs at 8–9 days and 21–22 days of postnatal age. Samples were analyzed via ELISA for anti-H1N1 hemagglutinin (anti-H1N1 HA) and anti-H3N2 neuraminidase (anti-H3N2 NA) specificity across immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) isotypes. The relative abundance of influenza A-specific IgA in feeds and gastric contents were higher in MBM than DBM at 8–9 days of postnatal age but did not differ at 21–22 days. Anti-influenza A-specific IgM was higher in MBM than in DBM at both postnatal times in feed and gastric samples. At both postnatal times, anti-influenza A-specific IgG was higher in MBM than DBM but did not differ in gastric contents. Gastric digestion reduced anti-H3N2 NA IgG from MBM at 21–22 days and from DBM at 8–9 days of lactation, whereas other anti-influenza A antibodies were not digested at either postnatal times. Supplementation of anti-influenza A-specific antibodies in DBM may help reduce the risk of influenza virus infection. However, the effective antibody dose required to induce a significant protective effect remains unknown.

6 August 2020 in Clinical Nutrition
Verified
Journal Article
Closed access
Robert BeverlyRobert Beverly
Robert Beverly
RHRobert Huston
Robert Huston
AMAndi M. Markell
Andi M. Markell
EMElizabeth A. McCulley
Elizabeth A. McCulley
RMRachel L. Martin
Rachel L. Martin
DDDavid Dallas
David Dallas

5 November 2019 in Journal of Neonatal-Perinatal Medicine
Verified
Journal Article
Open access
PDF file
RHRobert Huston
Robert Huston
MLM L Lee
M L Lee
ERE D Rider
E D Rider
MSM L Stawarz
M L Stawarz
DHD M Hedstrom
D M Hedstrom
HCH S Cohen
H S Cohen
BACKGROUND: An exclusive human milk diet (EHM) including fortification with a human milk-based fortifier has been shown to decrease the occurrence of necrotizing enterocolitis (NEC) but growth velocity may be less for infants receiving EHM compared to a bovine diet. OBJECTIVE: The objective of this study was to determine if growth is improved by earlier fortification of breast milk for preterm infants supported with a human milk based fortifier. STUDY DESIGN: A multi-center retrospective cohort study of the outcomes of infants of 500– 1250 g birth weight whose breast milk feedings were fortified at >60 mL/kg/day (late) versus <60 mL/kg/day (early) of enteral feeding volume. RESULTS: Median±IQR range for gestational age (27.6±3.4 vs 27.0±2.9 weeks, p = 0.03) and chronic lung disease (CLD: 42.6 vs 27.6%, p = 0.008) were higher, and weight gain (12.9±2.6 vs 13.3±2.6 g/kg/day, p = 0.03) was lower in the late (N = 102) vs the early (N = 292) group. Adjusted multiple linear regression analysis found that early fortification was associated with improved growth velocity for weight ( p = 0.007) and head circumference (HC) ( p = 0.021) and less negative changes in z-scores for weight ( p = 0.022) and HC ( p = 0.046) from birth to discharge. Adjusted multiple logistic regression found that early fortification was associated with decreased occurrence of CLD ( p = 0.004). No other outcomes, including NEC, were associated with early versus late fortification. CONCLUSION: The study results suggested that early HM fortification appears to positively affect growth for infants whose human milk feedings are fortified with a human milk based fortifier without adverse effects. The incidence of CLD was also reduced in the early fortification group.

14 February 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
RHRobert Huston
Robert Huston
JCJ. Mark Christensen
J. Mark Christensen
SASultan Alshahrani
Sultan Alshahrani
SMSumeia M. Mohamed
Sumeia M. Mohamed
CHCarl F. Heisel
Carl F. Heisel
There are no compatibility studies for neonatal parenteral nutrition solutions without cysteine containing calcium chloride or calcium gluconate using light obscuration as recommended by the United States Pharmacopeia (USP). The purpose of this study was to do compatibility testing for solutions containing calcium chloride and calcium gluconate without cysteine. Solutions of TrophAmine and Premasol (2.5% amino acids), containing calcium chloride or calcium gluconate were compounded without cysteine. Solutions were analyzed for particle counts using light obscuration. Maximum concentrations tested were 15 mmol/L of calcium and 12.5 mmol/L of phosphate. If the average particle count of three replicates exceeded USP guidelines, the solution was determined to be incompatible. This study found that 12.5 and 10 mmol/L of calcium and phosphate, respectively, are compatible in neonatal parenteral nutrition solutions compounded with 2.5% amino acids of either TrophAmine or Premasol. There did not appear to be significant differences in compatibility for solutions containing TrophAmine or Premasol when solutions were compounded with either CaCl2 or CaGlu-Pl. This study presents data in order to evaluate options for adding calcium and phosphate to neonatal parenteral nutrition solutions during shortages of calcium and cysteine.